aTyr Pharma (ATYR)
(Delayed Data from NSDQ)
$5.22 USD
+0.20 (3.98%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $5.22 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATYR 5.22 +0.20(3.98%)
Will ATYR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATYR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATYR
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year?
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates
ATYR: What are Zacks experts saying now?
Zacks Private Portfolio Services
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates
Other News for ATYR
aTyr Pharma management to meet with Cantor Fitzgerald
aTyr Pharma management to meet with Cantor Fitzgerald
Bearish Options Activity Observed in aTyr Pharma (ATYR)
aTyr Pharma Inc put volume heavy and directionally bearish
aTyr Pharma management to meet with Cantor Fitzgerald